AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32338433
Drug: rAHF 2
RxNorm normalized name: rAHF
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAHF 2 mL treatment
Trial: 32338621
Drug: Home-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based rehabilitation program driven by a tablet app and remote coaching (12-week program, exercises at least 5 days a week)
Trial: 32338621
Drug: Home-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based rehabilitation program driven by a tablet app and remote coaching
Trial: 32342016
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) combined with music therapy (10 therapy sessions and related homework)
Trial: 32342831
Drug: Dabigatran treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran treatment initiated within 14 days of TIA/minor stroke
Trial: 32343640
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg plus Nivolumab 3 mg/kg
Trial: 32343640
Drug: Regorafenib 80
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 80 mg plus Nivolumab 3 mg/kg
Trial: 32343640
Drug: Regorafenib 120
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 120 mg plus Nivolumab 3 mg/kg
Trial: 32344296
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss (±5% between diagnosis and post-treatment)
Trial: 32345378
Drug: Opicapone 50
RxNorm normalized name: opicapone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 50 mg (UK subgroup)
Trial: 32346071
Drug: nab-paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel 100 mg/smq on days 1, 8, 15 every 4 weeks up to six cycles, progressive disease or intolerable toxicity
Trial: 32346484
Drug: Home-based prehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based prehabilitation exercise intervention (increasing daily step-count during and after NAC)
Trial: 32347439
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for symptomatic children under five
Trial: 32349020
Drug: Heterogeneous dose-escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterogeneous dose-escalated prostate stereotactic body radiation therapy (target volume received 36.25 Gy/5 fx; target >3 mm from sensitive structures escalated to 50 Gy/5 fx)
Trial: 32349020
Drug: Heterogeneous dose-escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterogeneous dose-escalated prostate stereotactic body radiation therapy
Trial: 32349119
Drug: Escitalopram (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (8 weeks of open-label treatment)
Trial: 32350529
Drug: Empiric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric treatment (antibiotics and/or antifungals)
Trial: 32350529
Drug: Inappropriate prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate prescriptions
Trial: 32351419
Drug: Drug-induced parkinsonism
RxNorm normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-induced parkinsonism
Trial: 32352498
Drug: Nivolumab, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab, 240 mg intravenously every 2 weeks for 16 weeks, then 480 mg every 4 weeks until disease progression or unacceptable toxic effects.
Trial: 32352586
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine programme (DMP)
Trial: 32353110
Drug: Anticancer drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticancer drugs (19 identified drugs including lenalidomide, pomalidomide, nilotinib, ponatinib, midostaurin, azacytidine, clofarabine, docetaxel, obinutuzumab)
Trial: 32354451
Drug: Subcutaneous implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous implantable cardioverter-defibrillator (S-ICD) eligibility assessment
Trial: 32355442
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with Oculofolin containing 900 µg L-methylfolate for three months
Trial: 32355493
Drug: Ramucirumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (8 mg/kg every 2 weeks)
Trial: 32355503
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of alum-adjuvanted recombinant HBV vaccine
Trial: 32355503
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of alum-adjuvanted recombinant HBV vaccine
Trial: 32355836
Drug: Warfarin (VKA)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (VKA) with targeted INR 2-2.5
Trial: 32357963
Drug: MTL-CEBPA (28-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTL-CEBPA (28-160 mg/m) administered intravenously once a week for 3 weeks followed by a rest period of 1 week per treatment cycle
Trial: 32358769
Drug: Vagus Nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus Nerve Stimulation Therapy plus treatment-as-usual (VNS + TAU)
Trial: 32359671
Drug: Civil commitment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Civil commitment for drug misuse
Trial: 32360681
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of L-TAA and E-TAA
Trial: 32361007
Drug: FDG-PET/CT guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG-PET/CT guided adaptive radiation therapy (4 Gy boost on top of 70 Gy baseline dose)
Trial: 32361007
Drug: FDG-PET/CT guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG-PET/CT guided adaptive radiation therapy (78 Gy for partial metabolic response)
Trial: 32361007
Drug: FDG-PET/CT guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG-PET/CT guided adaptive radiation therapy (74 Gy for complete metabolic response)
Trial: 32361755
Drug: Oral cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cabotegravir (30 mg/day)
Trial: 32361755
Drug: Cabotegravir LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks)
Trial: 32362128
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) compliance measure (CCM)
Trial: 32364230
Drug: Substituting 1
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substituting 1 tablespoon/d (8 g · 2000 kcal-1 · d-1) of soybean oil
Trial: 32364844
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg spartalizumab intravenously, once every 4 weeks
Trial: 32366324
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin infusion at 3 mL/kg over 30 min
Trial: 32367609
Drug: Anal acoustic
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anal acoustic reflectometry (AAR) before and after rectal distension with 100 ml of air
Trial: 32367815
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg once daily in combination with sofosbuvir 400 mg for 12 weeks
Trial: 32367815
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg once daily
Trial: 32368162
Drug: Elbasvir/grazoprevir 50
RxNorm normalized name: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir/grazoprevir 50 mg/100 mg once daily for 12 weeks
Trial: 32368217
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy (ILIT) with a single preseason booster of 1000 SQ-U Alutard 5-grasses
Trial: 32368217
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy (ILIT) with standard dosing of 3000 SQ-U over 2 months
Trial: 32368692
Drug: Mirabegron (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (a β3AR agonist)
Trial: 32369480
Drug: Prednisone 40
RxNorm normalized name: prednisone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg daily for 3 days
Trial: 32371540
Drug: sorafenib, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib, 400 mg twice daily
Trial: 32371667
Drug: Nausea during
RxNorm normalized name: Pepto Nausea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nausea during treatment
Trial: 32371801
Drug: Decreased insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decreased insulin resistance
Trial: 32371801
Drug: Having triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Having triglycerides above 150 mg/dl
Trial: 32371801
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance index homeostatic model assessment
Trial: 32372294
Drug: ER ambroxol
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER ambroxol 75-mg retard capsules once daily
Trial: 32372294
Drug: IR ambroxol
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR ambroxol 60-mg effervescent tablets twice daily
Trial: 32372294
Drug: IR ambroxol
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR ambroxol 30-mg tablets twice daily
Trial: 32372416
Drug: DLL3-targeting antibody-drug
RxNorm normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLL3-targeting antibody-drug conjugate (Rovalpituzumab tesirine - Rova-T)
Trial: 32372672
Drug: PD-1 inhibitor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor, sintilimab, administered for three cycles.
Trial: 32373171
Drug: Spa treatment
RxNorm normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa treatment with radon water
Trial: 32374868
Drug: Clinical and
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical and imaging follow-up without occlusion treatment
Trial: 32375814
Drug: Transcatheter rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter rectal arterial chemoembolization (TRACE) with oxaliplatin and S-1 concurrent chemoradiotherapy (NATRACE-CRT)
Trial: 32375814
Drug: Standard fluorouracil-based
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard fluorouracil-based combined modality treatment (NA-CRT)
Trial: 32375872
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) treatment
Trial: 32377266
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Therapy
Trial: 32377287
Drug: Outpatient clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient clinic therapy
Trial: 32377978
Drug: DFP-11207, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFP-11207, administered orally daily, doses escalating from 40 mg/m²
Trial: 32379640
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (8 weekly sessions)
Trial: 32380537
Drug: Varlilumab (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varlilumab (0.1, 0.3, 1, 3, or 10 mg/kg IV) as a single dose with a 28-day observation period, followed by weekly dosing (4 doses per cycle, up to 5 cycles)
Trial: 32380537
Drug: Varlilumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varlilumab (0.3 mg/kg every 3 weeks, 4 doses per cycle, up to 5 cycles) in an expansion cohort of 4 patients with Hodgkin lymphoma
Trial: 32380536
Drug: Dose-dense immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense immunochemotherapy with early systemic CNS prophylaxis (2 courses of high-dose methotrexate, biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOEP and 1 course of high-dose cytarabine with R, plus intrathecal liposomal cytarabine at courses 1, 3, and 5)
Trial: 32380538
Drug: Ivosidenib (targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivosidenib (targeted mutant IDH1 enzyme inhibitor)
Trial: 32381080
Drug: Anti-mycobacterial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-mycobacterial treatment
Trial: 32381098
Drug: Qinbudan tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen (isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin for 2 months, followed by isoniazid, rifampicin, ethambutol for 6 months)
Trial: 32381098
Drug: Qinbudan tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen
Trial: 32381495
Drug: Clinic-based directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based directly observed therapy (DOT)
Trial: 32381630
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg orally per day for 12 months
Trial: 32382714
Drug: H4:IC31 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H4:IC31 vaccine (2 doses IM 56 days apart)
Trial: 32382714
Drug: H56:IC31 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H56:IC31 vaccine (2 doses IM 56 days apart)
Trial: 32382714
Drug: BCG revaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG revaccination (single dose ID)
Trial: 32383099
Drug: Alternative approaches
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative approaches (e.g., prevalence function, Q-TWiST, ToxT, recurrent event approaches)
Trial: 32383192
Drug: Bendamustine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine plus rituximab (first-line treatment)
Trial: 32383192
Drug: Bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), fludarabine, or ibrutinib (second-line treatment)
Trial: 32383296
Drug: Temporally Feathered
RxNorm normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporally Feathered Radiation Therapy (TFRT)
Trial: 36574408
Drug: Internet Attachment-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet Attachment-Based Compassion Therapy (iABCT)
Trial: 32384884
Drug: Vortioxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine treatment for 8 weeks
Trial: 32385144
Drug: Immunotherapic vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapic vaccine comprising phosphorylated BCAR3 peptide
Trial: 32385144
Drug: Immunotherapic vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapic vaccine comprising phosphorylated IRS2 peptide
Trial: 32385603
Drug: Isoglycaemic intravenous
RxNorm normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoglycaemic intravenous glucose infusions (IGIVI)
Trial: 32385845
Drug: 0.2% sirolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% sirolimus gel applied twice daily for > 52 weeks (maximum 136 weeks)
Trial: 32386106
Drug: Video directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video directly observed therapy (VDOT) adherence
Trial: 32386568
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) plus carboplatin and nab-paclitaxel (100 mg/m²) as neoadjuvant treatment.
Trial: 32387010
Drug: HIVAX therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVAX therapeutic HIV vaccine
Trial: 32388060
Drug: Registry data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Registry data collection from 232 MG patients
Trial: 32389183
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg) and glecaprevir-pibrentasvir (300 mg/120 mg) given one dose 6-12 hours before transplant and once a day for 7 days after surgery (total of 8 doses)
Trial: 32389229
Drug: Qualitative interviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative interviews and smartphone/tablet app reporting
Trial: 32390277
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg once daily for 7 days in a 28-day cycle)
Trial: 32392512
Drug: Oral glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoids (prednisolone-equivalent dose)
Trial: 32392512
Drug: Cumulative glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative glucocorticoid prednisolone-equivalent dose
Trial: 32393358
Drug: Validated paradigms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Validated paradigms (e.g., fear conditioning, reward anticipation, imaging stress test, social reward learning task)
Trial: 32394292
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (OACs) including dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban
Trial: 32395337
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 or 100 mg
Trial: 32395709
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system at a maximum dose of 160 mg/day
Trial: 32395709
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system
Trial: 32396014
Drug: One prior
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One prior administration of nivolumab and the cohort A regimen (5-FU+CDDP)
Trial: 32396014
Drug: One prior
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One prior administration of nivolumab and the cohort C regimen (docetaxel+ CF)
Trial: 32396615
Drug: CWP232291 (CWP291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CWP232291 (CWP291) administered IV daily for 7 days every 21 days
Trial: 32398128
Drug: Electrodermal activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrodermal activity (EDA) assessment during exposure therapy
Trial: 32398128
Drug: Subjective Units
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective Units of Distress Scale (SUDS) during exposure therapy
Trial: 32398478
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg subcutaneously
Trial: 32398792
Drug: elotuzumab therapy
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: elotuzumab therapy
Trial: 32399045
Drug: Bone Marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone Marrow Concentrate (BMC) with Platelet-Rich Plasma (PRP) and Platelet Lysate (PL) injections
Trial: 32399214
Drug: shRNA-IL6-modified anti-CD19
RxNorm normalized name: Anti-CD19 humanized monoclonal antibody conjugated to DM4
DrugBank: Coltuximab ravtansine (DB06342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: shRNA-IL6-modified anti-CD19 CAR-T therapy (ssCAR-T-19)
Trial: 32399263
Drug: MVT-5873 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVT-5873 (a cytotoxic monoclonal antibody targeting CA 19-9) administered as a single dose three days before resection and four post-operative infusions.
Trial: 32905959
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity